Will Illumina pull off its $7.1B bid to acquire Grail? EU regulators may have final say

The European Commission has until Nov. 29 to decide whether the acquisition of cancer diagnostic firm Grail would stifle competition. Illumina says blocking the deal will cost lives

Click here to view original post